Equities Analysts Issue Forecasts for Gilead Sciences Inc.’s FY2016 Earnings (GILD)
Gilead Sciences Inc. (NASDAQ:GILD) – Gabelli dropped their FY2016 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on Thursday. Gabelli analyst J. He now forecasts that the brokerage will post earnings of $11.01 per share for the year, down from their prior forecast of $11.26. Gabelli has a “Buy” rating and a $109.00 price objective on the stock.
A number of other equities research analysts have also recently weighed in on the stock. Piper Jaffray Cos. reissued a “buy” rating and issued a $108.00 price target on shares of Gilead Sciences in a research report on Monday, August 15th. Jefferies Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $76.89 to $91.00 in a research report on Tuesday, September 6th. Morgan Stanley reissued a “hold” rating and issued a $103.00 price target on shares of Gilead Sciences in a research report on Wednesday, June 15th. Berenberg Bank initiated coverage on shares of Gilead Sciences in a research report on Thursday. They issued a “buy” rating for the company. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Sunday, July 10th. Nine investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $105.41.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.05% on Friday, reaching $81.48. 4,010,094 shares of the company were exchanged. The company has a market capitalization of $107.53 billion, a P/E ratio of 7.15 and a beta of 1.06. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11. The stock has a 50 day moving average of $79.41 and a 200-day moving average of $85.94.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/23/equities-analysts-issue-forecasts-for-gilead-sciences-inc-s-fy2016-earnings-gild.html
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. Gilead Sciences’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period last year, the company posted $3.15 EPS.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.31%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s payout ratio is currently 16.56%.
In other news, Chairman John C. Martin sold 100,000 shares of the stock in a transaction on Friday, July 1st. The shares were sold at an average price of $84.73, for a total value of $8,473,000.00. Following the completion of the sale, the chairman now owns 4,119,727 shares of the company’s stock, valued at $349,064,468.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John F. Milligan sold 112,000 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the completion of the sale, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at approximately $98,747,309.79. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in GILD. CWM LLC raised its stake in Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 17 shares during the last quarter. Cadence Bank NA raised its stake in Gilead Sciences by 0.8% in the second quarter. Cadence Bank NA now owns 3,727 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 28 shares during the last quarter. Marble Harbor Investment Counsel LLC raised its stake in Gilead Sciences by 0.9% in the second quarter. Marble Harbor Investment Counsel LLC now owns 3,330 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 30 shares during the last quarter. Birch Hill Investment Advisors LLC raised its stake in Gilead Sciences by 0.9% in the second quarter. Birch Hill Investment Advisors LLC now owns 3,336 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 30 shares during the last quarter. Finally, Blume Capital Management Inc. raised its stake in Gilead Sciences by 0.9% in the second quarter. Blume Capital Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $459,000 after buying an additional 50 shares during the last quarter. 77.94% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.